Testing a new malaria vaccine in a controlled infection study
Treatments studied
Part of Infections clinical trials.
This study tests a new malaria vaccine by exposing volunteers to malaria parasites in a controlled setting. It aims to see if the vaccine can prevent infection and is looking for healthy adults of African origin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an African adult between 18 and 45 years old.
- You need to be in good general health and have no chronic illnesses.
- You must be willing to stay in a hospital for a short period after being exposed to malaria parasites.
- You cannot have participated in a malaria vaccine trial in the last 3 years.
- You must agree to use effective birth control during the study and for 12 weeks after the final vaccine dose or malaria exposure.
- You must live in or near the Bagamoyo district in Tanzania and plan to stay there for at least 9 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
This study tests an experimental malaria vaccine (CVD 36000) in healthy volunteers aged 18–50. Researchers will give you the vaccine and later expose you to malaria parasites in a controlled setting to see if the vaccine protects you. This helps develop a safer vaccine for people in malaria-prone countries.
This study compares two experimental malaria vaccines to see how safe they are and how well they protect adults. It may help future malaria prevention, and you would be closely monitored, including a malaria “challenge” test if you qualify.
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Hear when a new Malaria Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.